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i. Running head: Essential Features and Use Cases of CSF-PR 
 
ii. Summary/Abstract: 
Every year, a large number of published studies present biomarkers for various neurological 
disorders. Many of these studies are based on mass spectrometry proteomics data and describe 
comparison of the abundance of proteins in cerebrospinal fluid between two or more disease 
groups. As the number of such studies is growing, it is no longer straightforward to obtain an 
overview of which specific proteins are increased or decreased between the numerous 
relevant diseases and their many subcategories, or to see the larger picture or trends between 
related diseases. To alleviate this situation we therefore mined the literature for mass 
spectrometry-based proteomics studies including quantitative protein data from cerebrospinal 
fluid of patients with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease and 
organized the extracted data in the Cerebrospinal Fluid Proteome Resource (CSF-PR). CSF-
PR is freely available online at http://probe.uib.no/csf-pr, is highly interactive and allows for 
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easy navigation, visualization and export of the published scientific data. This chapter will 
guide the user through some of the most important features of the tool and show examples of 
the suggested use cases. 
 
iii. Key Words: mass spectrometry, cerebrospinal fluid, neurodegenerative/neurological 
disorders/diseases, biomarkers, data mining, data visualization, multiple sclerosis, Parkinson’s 
disease, Alzheimer’s disease 
 
1. Introduction 
Cerebrospinal fluid (CSF) surrounds the brain and spinal cord, and is believed to be a 
promising source for biomarkers for diseases affecting the central nervous system, as the 
detected proteins may reflect ongoing neurological processes [1-4]. Mass spectrometry-based 
proteomics is a method of choice for such studies and can measure thousands of proteins and 
peptides from a single sample.  
During the last 10-15 years numerous papers describing mass spectrometry results from CSF 
proteome mapping and biomarker studies have been published [5-9]. These types of studies 
often result in large data matrices, but usually only a small portion of the results are 
highlighted and discussed in the paper. Furthermore, while some authors provide all the 
underlying raw data (both identification and quantification), this is unfortunately not the 
default.  
We therefore saw the need to extract all protein and peptide related data across the relevant 
mass spectrometry studies and organize it in a common format for easy navigation, and make 
this information freely available to the scientific community. In 2014, we created the first 
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version of the CSF Proteome Resource (CSF-PR), mainly as a repository of the mass 
spectrometry data associated with our comprehensive CSF proteome mapping study [10]. The 
initial goal was to organize our large-scale CSF data in a structured manner, but also to share 
protein and peptide lists (with additional details) with other researchers.  
Next, we switched the focus to quantitative CSF data, resulting in an expanded and 
redesigned version of CSF-PR, to also include quantitative results, both from our own group 
and from other research groups. To achieve this, we mined the available literature for studies 
presenting protein abundance comparisons in CSF from patients with multiple sclerosis (MS), 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) , focusing on studies using mass 
spectrometry, and organized the extracted data in a revised version of CSF-PR, referred to as 
CSF-PR 2.0 [9].  
When choosing the data to include, we applied specific quality control filters for the literature 
searches related to technology, methodological set-up and sample size. Since the initial 
release of CSF-PR 2.0, an additional 12 datasets from 8 recent publications have been added 
[11-18], resulting in  CSF-PR now containing a total of 97 datasets from 25 publications. New 
relevant studies fulfilling the criteria are continuously being added.  
Several useful features for browsing, sorting, filtering and investigating the included data are 
available. This makes CSF-PR ideal for e.g. finding which proteins that are identified and 
quantified in CSF, investigating relevant literature for potential biomarker proteins, 
comparing protein abundances between diseases or selecting promising proteotypic peptides 





A description of CSF-PR features and a step-by-step guide through the resource is here 
presented, starting from the welcome page. The guide is divided into several sections for easy 
navigation and mainly focuses on the quantitative data.  
 
2.1 The CSF-PR welcome page 
When entering the CSF-PR web page, an overview of the resource status and sections is 
displayed (Figure 1). The user can choose to navigate to either (i) the manually curated 
quantitative data extracted from the publications [9], (ii) the identification data from the above 
mentioned CSF mapping paper [10], (iii) make a search across all resource data, or (iv)  
compare their own protein data to the data in the resource.  
 
2.2 Quantification data 
The quantification data tab takes you to an overview of the disease categories for which there 
is quantitative data in CSF-PR (Figure 2), and the user can choose an individual disease 
category or inspect all diseases at the same time. After selection, an overview of the selected 
data is presented as a heat map (Figure 3), displaying the different disease sub-categories for 
which data are available, plus the number of available datasets for each comparison. 
2.2.1 Filtering, customizing and investigating the quantitative data  
Several options for filtering, customizing and investigating the CSF-PR data are available. 
The user can either select specific comparisons from the heat map, or click Select all disease 
group comparisons in the bottom right corner to selects all datasets. Selection of cells will 
result in yellow edges around the cell. (See Note 1 and 2) 
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By navigating to the top left corner in the heat map, the Dataset filters window can be opened 
(Figure 4). This view provides an overview of the distribution of various data properties, 
related to publication year, study type, technology, analytical approach etc., and can be used 
to filter for specific data properties. Upon each selected filter, the pie charts are updated to 
display the current distribution, providing the user full control over the data being displayed. 
Given that different papers often use highly specific disease subgroups and because the 
categorization of the various disease subgroups is a subject of debate, we decided to use the 
same sub-group names in the heat map as is provided in the paper. However, we added the 
possibility to rename and combine existing groups. e.g. to reduce the number of disease sub-
group comparisons in the heat map and plots (Figure 5A, See Note 3). There is also a 
possibility to reorder the disease subgroups or exclude certain groups, to better organize and 
optimize the views and plots in the resource (Figure 5B). These features are available through 
the Recombine disease groups and Reorder and select disease groups icons in the top left 
corner of the heat map (See Figure 3). 
Whenever a selection is made from the heat map, new tabs/levels become visible to the right. 
The second tab includes a bubble plot providing an overview of the direction of regulation 
between the disease sub-groups for the currently selected proteins (Figure 6), with the bubble 
size representing the number of proteins changed in the specific direction between the disease 
sub-groups. One, several or all bubbles can be selected. By default, all are selected. 
The next tab provides a table with all the comparison- and protein-specific data. Plots 
showing the direction of regulation between all the disease group comparisons are shown for 
each protein. The table can be sorted on protein accession number or name, or on a specific 
value (direction of regulation) in a specific comparison (Figure 7) (See Note 4 and 5). 
6 
 
To view more details for a specific protein, the protein can be selected from the table, upon 
which a new Protein Details tab will become available below the Protein Table in the side 
panel. This tab presents all the results related to the selected protein from the relevant 
publications under the current filtration. The graph at the top summarizes the protein 
comparison results from each dataset in a single triangle as either Increased, Decreased or 
Equal (Figure 8) (See Note 6, 7, 8 and 9). Below the graph is a table containing the available 
peptide details from the datasets illustrated in the graph. This information can be useful in the 
selection of proteotypic peptides as is described in more details below. 
 
2.3 Searching for proteins or peptides 
The search tab in the home page allows the user to search for specific proteins (or peptides) 
across all or selected datasets in CSF-PR. This is useful to figure out if certain proteins are 
identified and/or quantified in CSF (See Note 10). It can also be used to inspect protein 
regulation across disease groups and categories. Multiple search keys are supported. 
2.3.1 Searching for a specific protein/peptide of interest - Basic 
1. Navigate to the Search tab in the CSF-PR welcome page. 
2. Type either protein name(s), accession number(s) or peptide sequence(s) and click the 
appropriate search term as well as the disease (if restricting the search to a specific 
disease). 
3. Load the results, which will then be visible in the same framework as described above. 
4. Observe the protein abundance status across various disease group comparisons in the 
plot. Expand to view a labelled x-axis. This plot shows the average results for all 
datasets quantifying this protein between the two specific disease groups. 
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5. Sort or filter the plot, drop comparisons from the view, flip disease groups A and B, or 
export to Excel using the icons in the bottom right corner. Click on any data point to 
view specific dataset details, as is described above. Click the accession number to 
view related UniProt (https://www.uniprot.org/) information about the specific protein. 
6. To view more detailed and dataset specific protein results, navigate to the Protein 
Details tab. Here, it becomes clear how many datasets that support the summarized 
results showed in the Protein Table.  
 
2.3.2 Evaluating/selecting biomarker candidates 
As part of a biomarker discovery project, it is necessary to evaluate the list of candidate 
proteins, in terms of their potential as markers of one or several categories (diagnostic, 
prognostic etc.). For this purpose, CSF-PR is a very useful tool, as it can easily give the user 
an overview of what other researchers have already found regarding your potential markers, 
in relation to MS, AD and PD. This can tell you something about each marker’s potential 
sensitivity and selectivity, and could also provide some indications as to which processes each 
marker can monitor.  
1. Navigate to the search section and insert the list of biomarker candidates to evaluate. 
Observe which one are found in the database. The proteins not found in CSF-PR might 
be difficult to identify or quantify using standard proteomics methods.  
2. Load the search results and inspect the candidate proteins abundance across the 
various disease group comparisons.  
3. By sorting the table in various ways, and perhaps merging and re-ordering the patient 
groups, interesting trends across disease categories and sub-groups can be revealed.  
Some questions that might be relevant in this setting: (i) Which studies have found the 
protein and what methods did they use? (ii) Is the protein only differentially expressed 
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in your disease of interest? (iii) Does the protein seem to be affected by treatment? (iv) 
If the protein is similarly affected across different diseases, which processes are 
common for these diseases? (v) What is the planned control group for your follow-
up/verification experiments? Is it suitable? 
4. By navigating to the heat map tab and clicking the dataset filters icon, you can observe 
the various features of the data, related to approaches (discovery/targeted) and specific 
quantification methods used, e.g. selected/parallel reaction monitoring (SRM/PRM), 
tandem mass tag (TMT) or label-free. If you, for example, are interested in using SRM 
or PRM for your follow up experiments, it may be a good idea to apply the filter for 
SRM/PRM or targeted and mass spectrometry, as you will then only see proteins that 
have previously been quantified by SRM/PRM. 
5. Based on the information obtained from CSF-PR one can hopefully arrive at a better 
selection of candidate markers to procced with in further experiments. 
 
2.3.3 Investigating peptide information for targeted assays (SRM/PRM) 
CSF-PR is a great tool to use if you are in the process of verifying potential biomarker 
candidates. Biomarker discovery experiments often result in a number of potential candidates, 
as outlined above. The selection of which peptides to use as surrogates for your proteins of 
interest is not always straightforward. Some guideline papers have been published on the 
selection of such peptides [23,24], but it can also be a good idea to observe which peptides 
have worked well for other researchers. To investigate peptide details for a protein of interest, 
follow these steps: 
1. Navigate to the Search panel and search for your protein of interest. You will see your 
results appearing if there are any hits for this protein in the resource. Hits can be either 
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in the identification data [10] or in the quantification data [9]. You can choose either 
to load only data for a specific disease category (MS, AD or PD) or to load all data.  
2. To get all available information on the protein, load all data. Your protein will appear 
alone in the protein table (See Note 11). Click in the table to open the next level tab, 
which is the Protein Details. 
3. In the Protein Details tab, all relevant peptide data for your protein of interest can be 
found in the table below the overview plot (See Figure 8).  
4. To view detailed dataset and protein specific information, click any of the triangles or 
the comparison in the table. 
5. To see the publication from which the specific dataset has been extracted, click the 
publication link, taking you to the publication in PubMed. 
6. The Protein Coverage section in the peptide overview gives information about which 
specific peptides have been used in each dataset to arrive at the final quantitative 
conclusion for the protein (See Figure 8). The coverage across the full protein 
sequence is here shown, and when available, also the quantitative results for each 
peptide, where abundance (increase, decrease, equal) and significance status is 
illustrated by colour coding. (See Note 12) 
7. Hover over the peptide to see the sequence plus the start and end indexes. 
8. Click a peptide to view detailed peptide specific data (e.g. sequence, fold change, p-
value, comments) in a pop-up window. 
You will find that not all peptides are identified for most proteins, or even has the same 
abundance or significance status, and there may be many reasons for this such as post-
translational modifications. This information is crucial in the selection of appropriate peptides 




2.4 Compare to your own data 
The compare section of CSF-PR makes it possible to insert protein results from your own 
experiments as the search key, and reveal how your protein data compares to what is 
previously known in the field.  
2.4.1 Comparison of your own data to the data in CSF-PR  
1. Navigate to the Compare tab in the CSF-PR welcome page. 
2. Select or enter the disease groups that best describe your specific comparison.  
3. Insert the list of protein accession numbers into the appropriate fields, based on their 
observed increased, decreased on equal abundance between the two disease groups 
used in your study.  
4. Click compare. The Results Overview will appear giving an overview of which 
proteins are found in the search, in which disease categories the proteins are found, 
plus the total number of hits. Make selections from the pie chart if desired, or load all 
data. 
5. After loading the data, the protein data will be available in the same framework (heat 
map, plots and tables) as described above, but the inserted user data is now integrated 
with the resource data (Figure 9). 
6. The data can now be inspected, sorted and filtered as described above, with the user 






Note 1: By default, only the CSF datasets are visible in the heat map, and pooled samples are 
included. Some serum datasets have also been included to the resource, if they represented 
verification of initial CSF studies. If the user wants to also display the serum datasets, this 
must be specifically selected by clicking the red drop symbol in the upper left corner of the 
heat map. In this area is also the possibility to remove datasets from studies that have 
employed pooling of samples. 
Note 2: In the lower right corner, other tabs are also available, such as the possibility to allow 
for multiple selections from the heat map, to clear filters and to export heat map data. It is also 
possible to view all the datasets and publications from which the datasets are collected. This 
overview will appear in a pop-up window, and clicking each dataset shows meta data for the 
dataset, related to e.g. experimental details, technology, protein and peptide numbers and 
patient features. A link to the original papers is also provided in this window. 
Note 3: The recombination of disease groups feature can be useful for advanced users, but 
should be used with caution. We recommend looking into the original publication for patient 
details. 
Note 4: Detailed sorting and filtering options for the protein table is available by clicking the 
Sort or filter comparison icon in the bottom right corner. Here, specific comparisons can also 
be removed from the table. The possibility to switch/flip disease groups is also available 
through the Switch disease groups icon, as is the opportunity to Clear all applied filters.  
Note 5: Data can be exported to Excel at this level and all other levels in CSF-PR. This is 
available through the Excel icon in the lower right corner. 
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Note 6: By default, all individual datasets are represented by individual data points, but the 
user can choose to see the summarized trend for all datasets combined by clicking the 
Show/hide individual datasets icon on the right. By selecting this view, only one averaged 
data point will be shown for each comparison. 
Note 7: Hover over each data point to see the details related to the disease groups compared, 
the number of patients and the p-value (if available), or click on a data point to get a pop-up 
with even more details related to the protein and the dataset. 
Note 8: The size of the triangle represents the number of patients in the specific study (the 
larger the triangle, the more patients included in the study). Furthermore, the colour and 
placement indicate the increased, decreased or equal abundance of the protein in the specific 
A vs. B comparison. 
Note 9: The graph can be ordered by trend by clicking the Order dataset by trend icon in the 
bottom right corner. 
Note 10: Please keep in mind that CSF-PR does not represent a complete overview of all 
proteins and peptides found in CSF, as not all types of publications are included. Some were 
excluded based on our specific criteria related to e.g. methods, patient number, disease groups 
or study type [9]. 
Note 11: To be able to see the disease group comparison, either hover over the specific data 
point in the plot or click the icon in the upper right corner of the plot window to get a labelled 
x-axis. 
Note 12: To see only the significantly changed peptides click the Show/hide not significant 
and stable peptides icon at the bottom right.
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Figure 1: Overview of the CSF-PR welcome page, where the different sections of the 
webpage can be accessed. A status of the data in the resource is shown in the upper left 






Figure 2: Overview of the available disease categories in CSF-PR. The user can click to view 
a selected disease category or to load data for all disease categories. Additionally, the number 
of datasets in each disease category is indicated as a fraction of the total number of datasets in 





Figure 3: Heat map displaying some of the available disease categories and disease sub-group 
comparisons. The number inside each cell shows the number of datasets available for this 




Figure 4: The Dataset Explorer allows the user to explore properties of the currently selected 
data, and filter for specific properties. Numbers in the charts indicate the number of data sets 






Figure 5: Pop-up dialogs where the user can (A) perform recombination or renaming of 




Figure 6: Bubble plot giving an overview of the number of proteins found increased, 






Figure 7: The protein table lists all the proteins under the current selection, and shows a plot 
illustrating how the proteins change across the various disease group comparisons. 
 
 
Figure 8: A: Overview of the datasets giving evidence for increased (red triangle), decreased 
(green triangle) or equal (blue square) abundance of the selected protein across the various 
comparisons (x-axis, not labelled in this view). Each data point represents a specific protein 
fold change (disease groups A vs. B) in a specific dataset. The specific comparison can be 
found by hovering over the symbol. B: Protein sequence coverage overview showing the 
peptides used for quantification in the specific selected dataset. Red indicates increased 
abundance and green indicated decreased abundance. Dark red and dark green indicates 








Figure 9: A: The bubble plot with integrated user data (far left), B: The protein table 
(expanded view to show the comparisons) with the user data results (increased) integrated and 
shown as a light red horizontal line. C: The protein details plot shown with the user data 
results (increased) integrated and shown as a light red horizontal line. D: The protein details 
plot shown with the user data results (decreased) integrated and shown as a light green 
horizontal line. 
 
 
 
